109 phenotypes from 8 alleles in 12 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Ank1ity16/Ank1+ involves: 129S1/Sv * 129X1/SvJ * DBA/2J	extramedullary hematopoiesis	J:199427
	increased erythrocyte cell number	J:199427
	increased kidney iron level	J:199427
	increased liver iron level	J:199427
	increased susceptibility to bacterial infection	J:199427
	increased susceptibility to bacterial infection induced morbidity/mortality	J:199427
Ank1ity16/Ank1ity16 involves: 129S1/Sv * 129X1/SvJ * DBA/2J	abnormal erythrocyte morphology	J:199427
	abnormal erythropoiesis	J:199427
	abnormal glomerular mesangium morphology	J:199427
	anisocytosis	J:199427
	decreased body weight	J:199427
	decreased erythrocyte cell number	J:199427
	decreased hematocrit	J:199427
	decreased hemoglobin content	J:199427
	decreased spleen iron level	J:199427
	enlarged spleen	J:199427
	glomerulonephritis	J:199427
	hemolytic anemia	J:199427
	increased blood urea nitrogen level	J:199427
	increased circulating alanine transaminase level	J:199427
	increased circulating aspartate transaminase level	J:199427
	increased circulating bilirubin level	J:199427
	increased heart weight	J:199427
	increased kidney iron level	J:199427
	increased kidney weight	J:199427
	increased leukocyte cell number	J:199427
	increased liver iron level	J:199427
	increased lymphocyte cell number	J:199427
	increased neutrophil cell number	J:199427
	increased susceptibility to bacterial infection	J:199427
	increased susceptibility to bacterial infection induced morbidity/mortality	J:199427
	jaundice	J:199427
	liver abscess	J:199427
	reticulocytosis	J:199427
Ank1M1Btlr/Ank1+ C57BL/6J-Ank1m1Btlr	decreased mean corpuscular hemoglobin	J:203831
	decreased mean corpuscular volume	J:203831
	hemolysis	J:203831
	increased circulating bilirubin level	J:203831
	increased erythrocyte cell number	J:203831
	increased erythrocyte osmotic fragility	J:203831
Ank1M1Btlr/Ank1M1Btlr C57BL/6J-Ank1m1Btlr	abnormal erythrocyte morphology	J:203831
	abnormal spleen morphology	J:203831
	decreased mean corpuscular hemoglobin	J:203831
	decreased mean corpuscular volume	J:203831
	enlarged spleen	J:203831
	extramedullary hematopoiesis	J:203831
	hemolysis	J:203831
	increased circulating bilirubin level	J:203831
	increased circulating erythropoietin level	J:203831
	increased erythrocyte cell number	J:203831
	increased erythrocyte osmotic fragility	J:203831
	increased spleen iron level	J:203831
	microcytosis	J:203831
	reticulocytosis	J:203831
	spherocytosis	J:203831
	stomatocytosis	J:203831
Ank1M1Wlst/Ank1+ C3.B6-Ank1M1Wlst	decreased cellular hemoglobin content	J:170562
	decreased mean corpuscular hemoglobin concentration	J:170562
	decreased mean corpuscular volume	J:170562
	increased erythrocyte cell number	J:170562
	increased erythrocyte osmotic fragility	J:170562
	polychromatophilia	J:170562
	reticulocytosis	J:170562
Ank1M1Wlst/Ank1+ involves: 129S1/SvImJ * C3H/HeJ * C57BL/6	abnormal erythrocyte morphology	J:170562
	enlarged spleen	J:170562
Ank1M1Wlst/Ank1+ involves: C3H/HeJ * C57BL/6	decreased cellular hemoglobin content	J:170562
	decreased mean corpuscular volume	J:170562
	increased erythrocyte cell number	J:170562
Ank1M1Wlst/Ank1M1Wlst C3.B6-Ank1M1Wlst	preweaning lethality, complete penetrance	J:170562
Ank1M1Wlst/Ank1M1Wlst involves: 129S1/SvImJ * C3H/HeJ * C57BL/6	abnormal common myeloid progenitor cell morphology	J:170562
	abnormal erythrocyte morphology	J:170562
	abnormal myelopoiesis	J:170562
	decreased birth weight	J:170562
	decreased body size	J:170562
	decreased body weight	J:170562
	decreased common myeloid progenitor cell number	J:170562
	decreased fetal weight	J:170562
	decreased hematocrit	J:170562
	enlarged heart	J:170562
	enlarged spleen	J:170562
	erythroblastosis	J:170562
	extramedullary hematopoiesis	J:170562
	gallstones	J:170562
	hemolytic anemia	J:170562
	increased erythroid progenitor cell number	J:170562
	increased nucleated erythrocyte cell number	J:170562
	jaundice	J:170562
	pallor	J:170562
	polychromatophilia	J:170562
	postnatal growth retardation	J:170562
	postnatal lethality, incomplete penetrance	J:170562
	premature death	J:170562
	reticulocytosis	J:170562
	spherocytosis	J:170562
Ank1M1Wlst/Ank1M1Wlst involves: C3H/HeJ * C57BL/6	abnormal leukocyte cell number	J:170562
	decreased hematocrit	J:170562
	decreased hemoglobin content	J:170562
	decreased mean corpuscular hemoglobin concentration	J:170562
	decreased mean corpuscular volume	J:170562
	increased erythrocyte cell number	J:170562
Ank1MRI23420/Ank1+ SJL/J-Ank1MRI23420	abnormal erythrocyte morphology	J:187820
	abnormal spleen morphology	J:187820
	anemia	J:187820
	decreased mean corpuscular hemoglobin	J:187820
	decreased mean corpuscular volume	J:187820
	decreased susceptibility to parasitic infection	J:187820
	decreased susceptibility to parasitic infection induced morbidity/mortality	J:187820
	enlarged spleen	J:187820
	hyperchromasia	J:187820
	increased erythrocyte cell number	J:187820
	increased erythrocyte osmotic fragility	J:187820
	increased spleen iron level	J:187820
	increased spleen weight	J:187820
	microcytosis	J:187820
	polycythemia	J:187820
	thrombocytosis	J:187820
Ank1MRI23420/Ank1MRI23420 SJL/J-Ank1MRI23420	abnormal erythrocyte morphology	J:187820
	enlarged spleen	J:187820
	increased spleen weight	J:187820
	jaundice	J:187820
	neonatal lethality, incomplete penetrance	J:187820
	poikilocytosis	J:187820
	postnatal lethality, complete penetrance	J:187820
	prenatal lethality, incomplete penetrance	J:187820
	spherocytosis	J:187820
Ank1nb/Ank1+ involves: C57BL/6J * WB/Re	abnormal erythrocyte morphology	J:111131
	decreased susceptibility to parasitic infection	J:111131
	increased erythrocyte protoporphyrin level	J:5985
Ank1nb/Ank1nb (WB.Cg-Ank1nb/BrkJ x B6.Cg-Ank1nb/BrkJ)F1	abnormal cardiac thrombosis	J:62355
	abnormal erythrocyte morphology	J:62355
	abnormal erythrocyte physiology	J:162532
	anisopoikilocytosis	J:162532
	cardiac hypertrophy	J:162532
	decreased body size	J:162532
	decreased hematocrit	J:162532
	decreased hemoglobin content	J:162532
	enlarged liver	J:162532
	enlarged spleen	J:162532
	extramedullary hematopoiesis	J:162532
	hemolysis	J:162532
	hemolytic anemia	J:162532
	increased circulating bilirubin level	J:162532
	increased erythrocyte clearance	J:162532
	increased erythrocyte osmotic fragility	J:162532
	increased nucleated erythrocyte cell number	J:162532
	infertility	J:162532
	jaundice	J:162532
	low mean erythrocyte cell number	J:162532
	microcytosis	J:62355
	poikilocytosis	J:162532
	preweaning lethality, incomplete penetrance	J:162532
	reticulocytosis	J:162532
	schistocytosis	J:162532
Ank1nb/Ank1nb either: (involves: non-inbred stock) or (involves: C57BL/6) or (involves: WB/Re)	abnormal bone marrow morphology	J:30699
	abnormal iron homeostasis	J:30699
	abnormal skin pigmentation	J:30699
	abnormal thymus development	J:30699
	cardiac hypertrophy	J:30699
	decreased body size	J:30699
	decreased erythrocyte cell number	J:30699
	decreased hematocrit	J:30699
	decreased hemoglobin content	J:30699
	enlarged liver	J:30699
	enlarged lymph nodes	J:30699
	enlarged spleen	J:30699
	gallstones	J:6371
	hypochromic anemia	J:30699
	impaired balance	J:11441
	increased leukocyte cell number	J:30699
	infertility	J:30699
	jaundice	J:30699
	Purkinje cell degeneration	J:11441
	tremors	J:11441
Ank1nb/Ank1nb involves: C57BL/6J * WB/Re	abnormal erythrocyte morphology	J:7501, J:42526, J:111131
	abnormal erythrocyte physiology	J:30033
	abnormal iron homeostasis	J:3122
	abnormal kidney iron level	J:3122
	acanthocytosis	J:111131
	anisocytosis	J:111131
	anisopoikilocytosis	J:111131
	decreased susceptibility to parasitic infection	J:111131
	hemosiderosis	J:3122
	increased erythrocyte protoporphyrin level	J:5985
	increased liver iron level	J:3122
	low mean erythrocyte cell number	J:3122
	microcytic anemia	J:3122
	microcytosis	J:111131
	poikilocytosis	J:111131
	reticulocytosis	J:3122, J:42526
	spherocytosis	J:3122
	stomatocytosis	J:111131
Ank1pale/Ank1pale C57BL/6J-Ank1pale/GrsrJ	abnormal skin pigmentation	J:154215
	decreased body size	J:154215
	postnatal lethality, complete penetrance	J:154215
	prenatal lethality, incomplete penetrance	J:154215
Ank1Rbc2/Ank1+ involves: 129S1/Sv * BALB/c	decreased mean corpuscular volume	J:148127
	decreased susceptibility to induced morbidity/mortality	J:148127
	decreased susceptibility to parasitic infection	J:148127
	increased erythrocyte osmotic fragility	J:148127
Ank1Rbc2/Ank1Rbc2 involves: 129S1/Sv * BALB/c	abnormal erythrocyte morphology	J:148127
	abnormal erythrocyte physiology	J:148127
	anemia	J:148127
	anisocytosis	J:148127
	decreased erythrocyte cell number	J:148127
	decreased hematocrit	J:148127
	decreased hemoglobin content	J:148127
	decreased mean corpuscular hemoglobin concentration	J:148127
	enlarged spleen	J:148127
	extramedullary hematopoiesis	J:148127
	increased circulating bilirubin level	J:148127
	increased erythrocyte osmotic fragility	J:148127
	increased hemoglobin concentration distribution width	J:148127
	increased liver iron level	J:148127
	increased nucleated erythrocyte cell number	J:148127
	jaundice	J:148127
	perinatal lethality, incomplete penetrance	J:148127
	poikilocytosis	J:148127
	postnatal lethality, incomplete penetrance	J:148127
	premature death	J:148127
	reticulocytosis	J:148127
	spherocytosis	J:148127
Ank1tm1Vso/Ank1tm1Vso B6J.129S4-Ank1tm1Vso	abnormal calcium ion homeostasis	J:223673
	abnormal diaphragm morphology	J:223673
	abnormal extensor digitorum longus morphology	J:223673
	abnormal muscle electrophysiology	J:223673
	abnormal sarcolemma morphology	J:223673
	abnormal sarcoplasmic reticulum morphology	J:223673
	abnormal skeletal muscle fiber triad morphology	J:223673
	impaired exercise endurance	J:223673
	impaired skeletal muscle contractility	J:223673
	myopathy	J:223673
	skeletal muscle fiber degeneration	J:223673